Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

1.1K
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
1.1K
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

2.4K
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
2.4K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

1.2K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.2K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

966
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
966
Principles of Disease Surveillance01:26

Principles of Disease Surveillance

563
Disease surveillance is the systematic collection, analysis, and interpretation of health data essential to the planning, implementation, and evaluation of public health practice. This process integrates data dissemination to entities responsible for preventing and controlling disease, injury, and disability. Surveillance systems provide crucial information for action, helping public health authorities make informed decisions to manage and prevent outbreaks, ensure public safety, optimize...
563
Psychoneuroimmunology: Cardiovascular Disease01:27

Psychoneuroimmunology: Cardiovascular Disease

577
Psychoneuroimmunology (PNI) is a multidisciplinary field that examines how psychological factors, particularly stress, interact with the immune system and impact physical health. Research in PNI has shown that chronic or traumatic stress can disrupt both the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system. These disruptions contribute to serious health conditions, including cardiovascular diseases.
A key area of focus in PNI is the relationship between stress and coronary...
577

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comment on 'Incidence and Mortality of Mucous Membrane Pemphigoid in France': reply from authors.

The British journal of dermatology·2026
Same author

Correction: Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program.

American journal of clinical dermatology·2026
Same author

Daratumumab as a therapeutic option for rituximab-recalcitrant pemphigus.

The Journal of investigative dermatology·2026
Same author

Tocilizumab for severe and refractory mucous membrane pemphigoid.

Journal of the European Academy of Dermatology and Venereology : JEADV·2026
Same author

Incidence and Mortality of Mucous Membrane Pemphigoid in France.

The British journal of dermatology·2026
Same author

Baricitinib and low-dose prednisone for very severe alopecia areata: A retrospective case series.

Journal of the European Academy of Dermatology and Venereology : JEADV·2026
Same journal

Microblading Technique for Tattooing of "Hairstrokes" That Simulate Natural Hair: Eyebrow Tattooing and Correction of Medical Conditions.

Current problems in dermatology·2023
Same journal

Preface.

Current problems in dermatology·2023
Same journal

On the Use, Effectiveness, and Safety of Face Masks, Gloves, and Disinfectants to Prevent Transfer of Microbials between the Tattooist and the Customer: A Practical Review of Pros and Cons Including the Occupational Safety of the Tattooist.

Current problems in dermatology·2023
Same journal

Linearity and Surface Anatomy of the Face: From Embryo to Senescence.

Current problems in dermatology·2023
Same journal

Stretch Mark Treatment by Tattooing and Microneedling.

Current problems in dermatology·2023
Same journal

Auxiliary Utensils in Cosmetic and Medical Tattoo Settings.

Current problems in dermatology·2023
See all related articles

Related Experiment Video

Updated: Feb 7, 2026

Author Spotlight: Exploring Non-Motor Symptoms in Parkinson's Disease
03:20

Author Spotlight: Exploring Non-Motor Symptoms in Parkinson's Disease

Published on: September 22, 2023

2.4K

Bullous Diseases.

Caroline Corbaux, Pascal Joly

    Current Problems in Dermatology
    |November 14, 2017
    PubMed
    Summary
    This summary is machine-generated.

    Rituximab shows promise for treating pemphigus and mucous membrane pemphigoid, with good tolerance. Omalizumab may benefit select bullous pemphigoid patients, particularly those with high immunoglobulin E levels.

    More Related Videos

    Author Spotlight: Establishing a New Fluorescence-Based Protocol for In Vivo Mitochondrial Morphology Analysis in Parkinson's Disease
    06:07

    Author Spotlight: Establishing a New Fluorescence-Based Protocol for In Vivo Mitochondrial Morphology Analysis in Parkinson's Disease

    Published on: June 23, 2023

    2.3K
    High Content Screening in Neurodegenerative Diseases
    13:32

    High Content Screening in Neurodegenerative Diseases

    Published on: January 6, 2012

    18.1K

    Related Experiment Videos

    Last Updated: Feb 7, 2026

    Author Spotlight: Exploring Non-Motor Symptoms in Parkinson's Disease
    03:20

    Author Spotlight: Exploring Non-Motor Symptoms in Parkinson's Disease

    Published on: September 22, 2023

    2.4K
    Author Spotlight: Establishing a New Fluorescence-Based Protocol for In Vivo Mitochondrial Morphology Analysis in Parkinson's Disease
    06:07

    Author Spotlight: Establishing a New Fluorescence-Based Protocol for In Vivo Mitochondrial Morphology Analysis in Parkinson's Disease

    Published on: June 23, 2023

    2.3K
    High Content Screening in Neurodegenerative Diseases
    13:32

    High Content Screening in Neurodegenerative Diseases

    Published on: January 6, 2012

    18.1K

    Area of Science:

    • Dermatology
    • Immunology
    • Rheumatology

    Background:

    • Autoimmune bullous diseases (AIBDs) are a diverse set of conditions causing skin and/or mucous membrane blistering.
    • Current primary treatments involve systemic corticosteroids and immunosuppressants.

    Purpose of the Study:

    • To review the efficacy and safety of key biologic agents in AIBD treatment.
    • To highlight rituximab's role in pemphigus and mucous membrane pemphigoid.
    • To explore omalizumab's potential in refractory bullous pemphigoid.

    Main Methods:

    • Literature review of current treatment strategies for AIBDs.
    • Analysis of data on rituximab and omalizumab use in AIBDs.
    • Evaluation of reported efficacy and adverse events.

    Main Results:

    • Rituximab is a viable treatment for pemphigus and mucous membrane pemphigoid, generally well-tolerated with rare severe side effects.
    • Omalizumab's efficacy in bullous pemphigoid (BP) is not well-established but shows potential in recalcitrant cases with elevated immunoglobulin E.
    • Both biologics demonstrate generally favorable safety profiles.

    Conclusions:

    • Rituximab is an effective therapeutic option for pemphigus and mucous membrane pemphigoid.
    • Omalizumab may offer a niche role in managing severe, refractory bullous pemphigoid.
    • Biologic therapies represent important advancements in AIBD management.